The document available here, entitled Final Report Analysis of a Clinical Trial Ribavirin and the Treatment of Lassa Fever and dated 7 February 1992, was obtained through a request under the U.S. Freedom of Information Act. The request was made on 1 March 2019 by Professor Peter Horby and the document was made available on 18 March 2019.
The document is a report of a meta-analysis of data from U.S. Centers for Disease Control and Sierra Leone Ministry of Health studies of the treatment of Lassa fever conducted in Sierra Leone between 1977 and 1991. The data described in the report, now for the first time publicly available, have significant limitations which are outlined both within the report and in an accompanying memo.
- The Final Report Analysis of a Clinical Trial Ribavirin and the Treatment of Lassa Fever. The data in the report were collected by the Centers for Disease Control (CDC) and funding for the study was provided by the U.S. Army Medical Research and Development Command.
How to cite: "Final Report Analysis of a Clinical Trial Ribavirin and the Treatment of Lassa Fever." report, 7 February 1992, SUBJECT: IND 16666 - Ribavirin (Virazole) (Serial No. 011), https://isaric.tghn.org/ribavirin-and-treatment-lassa-fever/final-report-analysis-clinical-trial-ribavirin-and-treatment-lassa-fever-7-february-1992/
- The second document is a letter dated 4 March 2019 from the U.S. Department of the Army to Professor Horby confirming the fulfillment of the FOIA request and describing potential limitations on the study contained in the Report.
How to cite: George V. Ludwig, Ph.D. to Dr. Peter William Horby, "On behalf of Major General Holcomb", memorandum, 4 March 2019, https://isaric.tghn.org/ribavirin-and-treatment-lassa-fever/george-v-ludwig-phd-dr-peter-william-horby/